open access

Vol 13, No 6 (2017)
Review paper
Published online: 2018-01-04
Get Citation

Bisphosphonates for the treatment of patients with cancer

Rafał Czyżykowski, Magdalena Krakowska, Piotr Potemski
DOI: 10.5603/OCP.2017.0040
·
Oncol Clin Pract 2017;13(6):268-274.

open access

Vol 13, No 6 (2017)
REVIEW ARTICLES
Published online: 2018-01-04

Abstract

Bisphosphonates inhibit osteoclasts activity and therefore reduce bone resorption. The main application of bisphosphonates in patients with cancer involves treatment of hypercalcemia, prevention of cancer treatment-induced bone loss, and decrease of the risk of skeletal-related events in patients with breast cancer or prostate cancer and bone metastases. For some time now there has been an increasing amount of data indicating that treatment with bisphosphonates improves survival of patients with early breast cancer. The activity is restricted to postmenopausal women or premenopausal patients whose treatment involves gonadotropin agonist.

Abstract

Bisphosphonates inhibit osteoclasts activity and therefore reduce bone resorption. The main application of bisphosphonates in patients with cancer involves treatment of hypercalcemia, prevention of cancer treatment-induced bone loss, and decrease of the risk of skeletal-related events in patients with breast cancer or prostate cancer and bone metastases. For some time now there has been an increasing amount of data indicating that treatment with bisphosphonates improves survival of patients with early breast cancer. The activity is restricted to postmenopausal women or premenopausal patients whose treatment involves gonadotropin agonist.
Get Citation

Keywords

bisphosphonates, breast cancer, prostate cancer

About this article
Title

Bisphosphonates for the treatment of patients with cancer

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 6 (2017)

Article type

Review paper

Pages

268-274

Published online

2018-01-04

DOI

10.5603/OCP.2017.0040

Bibliographic record

Oncol Clin Pract 2017;13(6):268-274.

Keywords

bisphosphonates
breast cancer
prostate cancer

Authors

Rafał Czyżykowski
Magdalena Krakowska
Piotr Potemski

References (46)
  1. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49(1): 2–19.
  2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9): 1032–1045.
  3. Van Acker HH, Anguille S, Willemen Y, et al. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. Pharmacol Ther. 2016; 158: 24–40.
  4. Coleman R, Body JJ, Aapro M, et al. ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014; 25 Suppl 3: iii124–iii137.
  5. Lester JE, Dodwell D, Purohit OP, et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clinical Cancer Research. 2008; 14(19): 6336–6342.
  6. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998; 90(9): 704–708.
  7. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010; 28(6): 967–975.
  8. Rhee Y, Song K, Park S, et al. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocr J. 2013; 60(2): 167–172.
  9. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013; 24(2): 398–405.
  10. Gnant M, Pfeiler G, Dubsky PC, et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(9992): 433–443.
  11. Wong MHF, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012(2): CD003474.
  12. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98(8): 1735–1744.
  13. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014; 15(1): 114–122.
  14. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003; 327(7413): 469.
  15. Kaminski M, Rosen L, Gordon D, et al. Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications. J Clin Oncol. 2004; 22(14_suppl): 857–857.
  16. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011; 29(9): 1221–1227.
  17. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008; 19(12): 2007–2011.
  18. Powles T, McCroskey E, Paterson A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006; 8(2): R13.
  19. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001; 19(1): 10–17.
  20. Paterson AHG, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012; 13(7): 734–742.
  21. Zhu J, Zheng Y, Zhou Z. Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis. Eur J Cancer. 2013; 49(9): 2086–2092.
  22. von Minckwitz G, Möbus V, Schneeweiss A, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013; 31(28): 3531–3539.
  23. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 2008; 47(4): 740–746.
  24. Coleman R, Cameron D, Dodwell D, et al. AZURE investigators. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014; 15(9): 997–1006.
  25. Gnant M, Mlineritsch B, Stoeger H, et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26(2): 313–320.
  26. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015; 386(10001): 1353–1361.
  27. Gralow J, Barlow WE, Paterson AH, et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307 J Clin Oncol. 2015; 33(suppl).
  28. Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016; 27(3): 379–390.
  29. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001; 345(13): 948–955.
  30. Serpa Neto A, Tobias-Machado M, Esteves MAP, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012; 15(1): 36–44.
  31. Choo R, Lukka H, Cheung P, et al. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1239–1245.
  32. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361(8): 745–755.
  33. Dearnaley DP, Sydes MR, Mason MD, et al. Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003; 95(17): 1300–1311.
  34. Dearnaley DP, Mason MD, Parmar MKB, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009; 10(9): 872–876.
  35. Smith M, Halabi S, et al. Ryan ChJ Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol. 2014; 32: 1143–1150.
  36. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet. 2016; 287: 1163–1177.
  37. Vale CL, Burdett S, Rydzewska LHM, et al. STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016; 17(2): 243–256.
  38. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003; 21(23): 4277–4284.
  39. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003; 21(17): 3335–3342.
  40. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458–1468.
  41. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96(11): 879–882.
  42. Mason MD, Sydes MR, Glaholm J, et al. Medical Research Council PR04 Collaborators. Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007; 99(10): 765–776.
  43. Dearnaley DP, Mason MD, Parmar MKB, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009; 10(9): 872–876.
  44. Wirth M, Tammela T, Cicalese V, et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2015; 67(3): 482–491.
  45. Hortobagyi GN, Van Poznak C, Harker WG, et al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017; 3(7): 906–912.
  46. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017; 317(1): 48–58.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl